Program
Autologous Anti-DLL3 CAR-T Cells DJI136
Also written as “DJI136” and “LB2102”.
In Novartis’s pipeline, DLL3 CAR-T
. Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Neuroendocrine, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Legend Biotech USAits history only | 11 open or running | phase 1since Dec 21, 2022 | Dec 21, 2022 | Dec 2027phase 1 · NCT05680922 |
| Novartisits history only | 11 open or running | phase 2since Apr 27, 2026 | Apr 27, 2026 | Mar 3, 2031phase 2 · NCT07564401 |
- Named in Novartis’s own pipeline as
DJI136
, phase 1, as of Nov 16, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 21, 2022First study: phase 1 study in Small Cell Lung Cancer Extensive StageNew to Legend Biotech USALegend Biotech USA · NCT05680922 · 41 enrolled · United States
- Apr 27, 2026Novartis’s first study: phase 2 study in Small Cell Lung CarcinomaNew to NovartisNovartis · NCT07564401 · 80 planned · United States, Australia, Singapore and more
Ahead
- Dec 2027Primary completion: phase 1 study in Small Cell Lung Cancer Extensive StageLegend Biotech USA · NCT05680922
- Mar 3, 2031Primary completion: phase 2 study in Small Cell Lung CarcinomaNovartis · NCT07564401
TargetBeta
“DLL3 CAR-T”the company's pipeline, read by Claude · source
“A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), ”NCIt, by rule
Other programs on DLL3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| Zocilurtatug Pelitecanrule | Zai Lab | phase 3 | 6 |
| Anti-DLL3 Antibody-drug Conjugate BL-M14D1 | Sichuan Biokin Pharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Anti-DLL3 Antibody-drug Conjugate IDE849 | ideaya-biosciences | phase 2 | 2 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| Anti-DLL3 Antibody-drug Conjugate FZ-AD005rule | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | phase 1 | 2 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| Actinium Ac 225-ABD147rule | abdera-therapeutics-inc | phase 1 | 1 |
| Indium In 111-ETN029 | Novartis | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07564401Small Cell Lung Carcinoma · United States, Australia, Singapore and more | 2 | Recruiting | Novartis | Mar 3, 2031 | 80 |
| NCT05680922Small Cell Lung Cancer Extensive Stage · United States | 1 | Active, not recruiting | Legend Biotech USA | Dec 2027 | 41 |
How it is read
Names in the registry
- “DJI136”, 1 entry
- “LB2102”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
- Carcinoma, Neuroendocrine, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.